跳至主要内容
临床试验/NCT01674907
NCT01674907已完成不适用

Non-interventional Study of Avastin in 1st Line Metastatic Colorectal Cancer

Hoffmann-La Roche0 个研究点目标入组 27 人开始时间: 2010年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
27
主要终点
Clinical/demographic patient characteristics at baseline

研究概览

简要总结

This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients, >/= 18 years of age
  • Histologically confirmed metastatic colorectal cancer without prior chemotherapy in the metastatic setting

排除标准

  • Contraindications for Avastin according to the locally approved package insert (version 7 April 2006)

结局指标

主要结局

Clinical/demographic patient characteristics at baseline

时间窗: approximately 3 years

Dosage/schedule of 1st-line Avastin

时间窗: approximately 3 years

Chemotherapy regimens used in clinical practice

时间窗: approximately 3 years

Duration of treatment

时间窗: approximately 3 years

次要结局

  • Relationship between termination of Avastin treatment and time point of progression(approximately 3 years)
  • Progression-free survival(approximately 3 years)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验